3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Breast Neoplasms
14
Neoplasms
10
Head and Neck Neoplasms
8
Carcinoma, Squamous Cell
8
Lung Neoplasms
7
Leukemia, Myeloid, Acute
7
Glioblastoma
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Recurrence
5
Pancreatic Neoplasms
5
Melanoma
5
Leukemia
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Fallopian Tube Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Rectal Neoplasms
3
Lymphoma, Follicular
3
Colonic Neoplasms
3
Brain Neoplasms
3
Treatment
2
Sarcoma
2
Pleural Effusion, Malignant
2
Pharyngeal Neoplasms
2
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
Drug Therapy
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts